This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
nmo
NMOSD
NMOSD: AQP4-IgG+ (85%) or MOG-IgG+ attacks on optic nerves, spinal cord, and brainstem (area postrema); relapsing; high morbidity. Eculizumab (PREVENT; FDA Jun 2019), inebilizumab (N-MOmentum; FDA Jun 2020), satralizumab (SAkuraStar; FDA Aug 2020) approved.
Entry Metadata
| Field | Value |
|---|---|
| ID | nmo |
| Name | NMOSD |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. · PubMed 26092914
- Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614-625. · PubMed 31050279
- Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum). Lancet. 2019;394(10206):1352-1363. · PubMed 31495497
- Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114-2124. · PubMed 31774951